dr. pal on sequencing abiraterone and enzalutamide in mcrpc
Published 10 years ago • 231 plays • Length 1:12Download video MP4
Download video MP3
Similar videos
-
0:55
dr. pal on sequencing abiraterone and enzalutamide in mcrpc
-
1:27
dr. mark scholz on using abiraterone in mcrpc
-
1:52
treatment sequencing in mcrpc: cabazitaxel vs. abiraterone or enzalutamide
-
2:09
dr. charles ryan discusses abiraterone and enzalutamide for mcrpc
-
4:59
an overview of sequencing in mcrpc
-
5:19
xtandi patient stories
-
46:31
prostate specific membrane antigen (psma) ligands for diagnosis and therapy of prostate cancer
-
2:41
rob's prostate cancer story and successful treatment with abiraterone
-
2:49
overall survival data in mcrpc
-
1:53
dr. nicholas vogelzang discusses sequencing abiraterone and enzalutamide
-
3:09
mcrpc: sequencing therapy
-
8:12
the use of abiraterone and enzalutamide against crpc
-
2:19
tomasz m. beer md, facp, on the efficacy of abiraterone enzalutamide in mcrpc
-
1:14
dr. dreicer on abiraterone and enzalutamide in prostate cancer
-
1:39
dr. howard scher on corticosteroids during treatment with enzalutamide in mcrpc
-
0:46
ctc hoxb13 rna in mcrpc: abiraterone/enzalutamide impact
-
0:54
convincing long-term survival with abiraterone in mcrpc
-
3:06
the best therapy option for a patient with mcrpc
-
0:45
dr. hahn on patients with prostate cancer whom neither docetaxel or abiraterone is an option
-
1:07
dr. penson on treatment selection in metastatic hormone-sensitive prostate cancer
-
1:34
dr. mary-ellen taplin on the mechanism of action of enzalutamide (mdv3100)
-
1:12
dr. dreicer on the current role of abiraterone and enzalutamide in prostate cancer